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BACKGROUND: Glucagon-like peptide-1 receptor (GLP-1R) agonists 
improve cardiovascular outcomes in patients with type 2 diabetes mellitus. 
However, systemic actions of these agents cause sympathetic activation, 
which is generally considered to be detrimental in cardiovascular disease. 
Despite significant research interest in cardiovascular biology of GLP-1, the 
presence of GLP-1R in ventricular cardiomyocytes remains a controversial 
issue, and the effects of this peptide on the electrical properties of intact 
ventricular myocardium are unknown. We sought to determine the effects 
of GLP-1R agonist exendin-4 (Ex4) on ventricular action potential duration 
(APD) and susceptibility to ventricular arrhythmia in the rat heart in vivo 
and ex vivo.
METHODS: Ventricular monophasic action potentials were recorded in 
anaesthetized (urethane) rats in vivo and isolated perfused rat hearts 
during sinus rhythm and ventricular pacing.
RESULTS: In vivo, systemic administration of Ex4 (5 μg/kg 
intravenously) increased heart rate, and this effect was abolished by 
β-adrenoceptor blockade. Despite causing sympathetic activation, 
Ex4 increased APD at 90% repolarization during ventricular pacing by 
7% (P=0.044; n=6) and reversed the effect of β-adrenoceptor agonist 
dobutamine on APD at 90% repolarization. In isolated perfused hearts, 
Ex4 (3 nmol/L) increased APD at 90% repolarization by 14% (P=0.015; 
n=6) with no effect on heart rate. Ex4 also reduced ventricular 
arrhythmia inducibility in conditions of β-adrenoceptor stimulation 
with isoproterenol. Ex4 effects on APD and ventricular arrhythmia 
susceptibility were prevented in conditions of muscarinic receptor 
blockade or inhibition of nitric oxide synthase.
CONCLUSIONS: These data demonstrate that GLP-1R activation 
effectively opposes the effects of β-adrenoceptor stimulation on cardiac 
ventricular excitability and reduces ventricular arrhythmic potential. The 
effect of GLP-1R activation on the ventricular myocardium is indirect, 
mediated by acetylcholine and nitric oxide and, therefore, can be 
explained by stimulation of cardiac parasympathetic (vagal) neurons.
VISUAL OVERVIEW: A visual overview is available for this article.
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GLP-1 (glucagon-like peptide-1) is an incretin hor-mone produced predominantly by L-cells of the gut in response to the ingestion of food. GLP-1 
plays an important role in the physiological control of 
glucose metabolism and energy homeostasis.1 GLP-1 
receptor (GLP-1R) agonists are currently in clinical use 
for the treatment of diabetes mellitus and obesity.2 Be-
cause of significant beneficial effects of GLP-1R agonists 
on the cardiovascular system (including anti-inflamma-
tory, antiatherogenic, positive inotropic, glucose up-
take stimulating, and vasodilatory effects),2 GLP-1 has 
become the most extensively studied incretin. Based 
on significant preclinical data, large-scale clinical trials 
were initiated to test the efficacy of GLP-1R agonists on 
cardiovascular outcomes in various patient cohorts. A 
recent influential study conducted in ≈10 000 patients 
with type 2 diabetes mellitus demonstrated significant 
reduction in frequency of adverse cardiovascular events 
and death from cardiovascular causes by treatment 
with GLP-1 analogue liraglutide.3
GLP-1 acutely increases heart rate (HR), and this 
effect of GLP-1 on nodal tissue appears to be indirect, 
mediated via increased activity of the sympathetic ner-
vous system.4,5 Despite triggering sympathetic activa-
tion and increases in HR (which would be expected to 
increase myocardial oxygen demands, worsen myocar-
dial injury, and promote arrhythmias), GLP-1R agonists 
have been found to effectively protect cardiomyocytes 
against ischemia/reperfusion injury in animal mod-
els2,3,6,7 and in humans.8 There is also evidence that 
GLP-1 may function as a humoral factor that medi-
ates the innate mechanisms of remote ischemic pre-
conditioning cardioprotection.9,10 However, despite 
significant research interest in cardiovascular biology 
of GLP-1, the presence of GLP-1R in ventricular car-
diomyocytes remains a controversial issue,11,12 and 
the effects of the peptide on the electrical properties 
of intact ventricular myocardium and in vivo remain 
unknown. This study conducted in experimental ani-
mals (rats) investigated the effect of GLP-1R activation 
on the ventricular electrophysiological properties in 
vivo and in isolated heart preparations. We hypoth-
esized that this approach would also reveal the pres-
ence of functional GLP-1R in ventricular myocytes if 
(1) the actions of GLP-1R agonist are associated with 
significant changes in the electrical properties of the 
ventricular myocardium, (2) these effects of GLP-1R 
agonist are preserved in isolated hearts, and (3) the 
effects of GLP-1R agonist are preserved in conditions 
when common autonomic effector signaling mecha-
nisms are blocked pharmacologically.
METHODS
The data, analytic methods, and study materials are avail-
able to other researchers for purposes of reproducing the 
results or replicating the procedures. All experiments were 
performed in accordance with the European Commission 
Directive 2010/63/EU (European Convention for the 
Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes) and the UK Home Office 
Scientific Procedures Act (1986) with project approval 
from the respective Institutional Animal Welfare and 
Ethical Review Bodies.
Experiments In Vivo
Adult male Sprague-Dawley rats (250–340 g) were anaes-
thetized with urethane (1.3 g/kg intraperitonially). The 
right femoral artery and vein were cannulated for measure-
ment of the arterial blood pressure and administration of 
pharmacological agents, respectively. The trachea was can-
nulated, and the animal was mechanically ventilated with 
room air using a positive pressure ventilator (tidal volume 
≈1 mL per 100 g of body weight, ventilator frequency 60 
strokes/min). Adequate level of anesthesia was ensured by 
monitoring stability of arterial blood pressure and HR and 
the absence of a withdrawal response to a paw pinch. Po2, 
Pco2, and pH of the arterial blood were measured regu-
larly, and (if required) ventilation was adjusted to maintain 
these variables within the physiological ranges. The body 
temperature was maintained at 37°C±0.5°C with a servo-
controlled heating pad.
The heart was exposed via a left thoracotomy, and a bipo-
lar silver pacing electrode was fixed to the right ventricular 
apex using a 4-0 monofilament polypropylene suture. Pacing 
stimuli were delivered (S88-Grass stimulator) at twice the 
diastolic threshold. Ventricular monophasic action potential 
(MAP) was recorded using a custom-made suction electrode 
placed directly onto the epicardial surface of the left ventricle. 
Arterial blood pressure, a standard lead II ECG, and ventricu-
lar MAP signals were recorded using Power1401 interface 
and analyzed offline using Spike2 software (Cambridge 
Electronic Design Ltd).
WHAT IS KNOWN?
• GLP-1 (glucagon-like peptide-1) receptor agonists 
improve cardiovascular outcomes in patients with 
type 2 diabetes mellitus.
• Despite significant research interest in cardiovascu-
lar biology of GLP-1, the presence of GLP-1 receptor 
in ventricular cardiomyocytes remains a controver-
sial issue, and the effects of this peptide on the elec-
trical properties of intact ventricular myocardium 
are unknown.
WHAT THE STUDY ADDS?
• GLP-1 receptor activation opposes sympathetic 
effects on cardiac ventricular excitability and 
reduces ventricular arrhythmic potential.
• These effects are indirect, mediated by acetylcho-
line and nitric oxide, and can be explained by facili-
tated release of these signaling molecules from the 
ventricular terminals of cardiac vagal neurons.
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Action potential duration (APD) at 90% repolarization 
(APD90) was determined in sinus rhythm and during ventricu-
lar pacing at ≈500 bpm to allow APD90 comparisons at fixed 
HR. Values of HR and PR interval were averaged from 10 con-
secutive beats during steady state for each condition. Pacing 
was performed for 1 minute, and APD90 measurements were 
taken after averaging of MAP in the last 10 seconds when the 
recording had stabilized. The MAP amplitude was measured 
as the distance from the diastolic baseline to the crest of the 
MAP plateau phase, not the peak of the upstroke. The ampli-
tude of the recorded MAP signal was generally in the range of 
5 to 15 mV. The MAP duration was measured as the interval 
from the steepest part of the MAP upstroke (or the intrin-
sic deflection, if discernible) to the 90% repolarization level 
along a line horizontal to the diastolic baseline, as described.13
In a group of 6 rats, MAP morphology was sequen-
tially assessed: (1) at baseline; (2) in conditions of systemic 
β-adrenoceptor (β-AR) stimulation with isoproterenol (Iso; 2 
μg/kg intravenously); (3) following washout of Iso effect (≈10 
minutes after administration of Iso); (4) in conditions of sys-
temic administration of GLP-1R agonist exendin-4 (Ex4; 5 μg/
kg intravenously), and then following autonomic blockade 
with (5) β-AR blocker atenolol (2 mg/kg intravenously); and 
finally (6) muscarinic receptor antagonist atropine (2 mg/kg 
intravenously; n=3) or neuronal nitric oxide (NO) synthase 
inhibitor 7-nitroindazole (25 mg/kg intraperitonially; n=3) 
administration (Figure  1Ai). The 5 μg/kg dose of Ex4 was 
chosen based on the results of published studies that demon-
strated potent cardioprotection of GLP-1R activation in vivo.9,14
In a separate group of 5 rats, MAP was sequentially 
assessed: (1) at baseline, (2) in conditions of systemic admin-
istration of a longer acting β-AR agonist dobutamine (1.5 mg/
kg intraperitonially), and (3) in conditions of systemic coad-
ministration of dobutamine (1.5 mg/kg intraperitonially) and 
Ex4 (5 μg/kg intravenously; Figure 1Aii).
Experiments in Isolated Heart Preparation
Sprague-Dawley rats (125–150 g) were terminally anaes-
thetized with pentobarbital sodium (100 mg/kg intraperi-
tonially). Hearts were excised after thoracotomy, placed 
in ice-cold Krebs solution (NaCl 118 mmol/L, KCl 4.75 
mmol/L, MgSO4 1.19 mmol/L, NaHCO3 25 mmol/L, KH2PO4 
1.19 mmol/L, d-glucose 5 mmol/L, CaCl2 1.4 mmol/L, and 
pyruvate 2 mmol/L), cannulated via the aorta, and mounted 
onto a Langendorff apparatus to establish retrograde per-
fusion via the ascending aorta with oxygenated Krebs solu-
tion at a constant flow of 2 mL/min. Ventricular MAP was 
recorded using Franz contact electrode (ADInstruments) 
placed directly onto the epicardial surface of the left ven-
tricle. The temperature of the preparation was maintained 
at 37.0°C±0.5°C. ECG and MAP signals were recorded 
using Power1401 interface and analyzed offline using 
Spike2 software. Experimental protocols commenced after 
a 15-minute stabilization period. To deliver ventricular pac-
ing, a custom-made bipolar silver electrode was placed 
onto the apex of the right ventricle. Using a constant cur-
rent stimulator (Digitimer DS7A), a train of 15 pulses was 
applied (S1, 0.5 mA; cycle length, 110 ms), followed by 
an incrementally shortened period before application of an 
extra single pulse (S2) until failure of ventricular capture. 
APD90 was determined after averaging of the last 3 paced 
beats of all S1 pacing trains. To assess susceptibility to ven-
tricular arrhythmia, the number of ventricular extrasystoles 
induced after each S2 pulse was counted with ≥4 ventricu-
lar extrasystoles defined as ventricular tachycardia.
In a group of 6 hearts, APD90 and ventricular arrhythmia 
susceptibility were assessed: (1) at baseline, (2) in conditions 
of β-AR stimulation with Iso (100 nmol/L), (3) after adminis-
tration of Ex4 (3 nmol/L), and finally, (4) in conditions of Iso 
(100 nmol/L) and Ex4 (3 nmol/L) coadministration (Figure 2A). 
For these experiments, the 3 nmol/L dose of Ex4 was chosen 
based on the results of published studies which demonstrated 
potent cardioprotection of GLP-1R activation in isolated 
rodent hearts.15–17
In 2 separate experimental groups, the effects of Ex4 were 
also assessed in conditions of muscarinic receptor blockade 
with atropine (1 μmol/L; n=6) and NO synthase inhibition with 
L-NG-monomethyl arginine (100 μmol/L; n=6; Figure 2A).
Statistical Analysis
Data are reported as individual values, means±SEM, or as box 
and whiskers plots. Groups were compared by repeated mea-
sures ANOVA with Greenhouse-Geisser correction followed 
by Tukey post hoc test. Categorical data were compared by 
χ2test and Fisher exact test. Differences between the groups 
or treatments with P<0.05 were considered to be significant. 
Statistical analysis was performed using GraphPad Prism 7 
software. The data that support the findings of this study are 
available from the corresponding authors on request.
RESULTS
Effects of GLP-1R Agonist Ex4 on HR and 
Electrical Properties of the Ventricular 
Myocardium In Vivo
Because systemic actions of GLP-1R agonists increase 
HR indirectly via triggering sympathetic activation, we 
first compared the effects of Ex4 to that of β-AR ago-
nist Iso. Systemic administration of Iso (2 μg/kg intra-
venously) increased HR from 322±9 to 423±11 bpm 
(P<0.001; n=6) and reduced PR interval from 54.2±1.3 
to 50.5±1.0 ms (P=0.003; Figure 1C). Iso also reduced 
APD90 (from 53.2±1.5 to 44.9±1.6 ms; P=0.022; Fig-
ure 1B and 1Di).
Ex4 (5 μg/kg intravenously, administered after allow-
ing the effect of Iso to plateau during washout) increased 
HR (from 367±9 to 460±6 bpm; P<0.001) and reduced 
PR interval (from 52.5±1.3 to 47.3±1.1 ms; P=0.001; 
Figure  1C). Because HR and PR interval at washout 
were slightly different when compared with the base-
line (reflecting incomplete Iso washout), the magnitude 
of Ex4 effect on these variables is likely to be somewhat 
underestimated. Importantly, in contrast to the effect of 
Iso, Ex4 prolonged ventricular APD90 (52.4±1.9 versus 
47.8±1.9 ms; P=0.006; Figure 1B and 1Di). Administra-
tion of β-AR antagonist atenolol reversed the effects of 
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Figure 1. Effects of GLP-1 (glucagon-like peptide-1) receptor activation on heart rate and electrical properties of the ventricular myocardium in vivo. 
A, Experimental protocols of the in vivo experiments. Arrows depict time points when physiological measurements were taken; (B) Representative recordings of 
monophasic action potential illustrating the effects of isoproterenol (Iso, 2 μg/kg intravenously) and exendin-4 (Ex4, 5 μg/kg intravenously) on action potential 
duration at 90% repolarization (APD90); (C) Effects of Iso and Ex4 on heart rate (HR, Ci) and PR interval (Cii); (D) Summary data showing the effects of Iso and Ex4 
on APD90 during sinus rhythm (Di) and during fixed pacing (Dii); (E) Effects of dobutamine (Dob, 1.5 mg/kg intraperitonially) and coadministration of Dob (1.5 mg/
kg intraperitonially) and Ex4 (5 μg/kg intravenously) on APD90 in fixed HR conditions. *P<0.05, **P<0.01, ***P<0.001.
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Ex4 on HR and PR interval (Figure 1C) but had no effect 
on APD90 changes induced by Ex4 (P=0.285). Both atro-
pine and 7-nitroindazole administered after Ex4, reduced 
APD90 by the same degree (to 40.1±0.7 and 41.5±2.9 
ms, respectively; P=0.002 compared with Ex4).
To separate the effects of GLP-1R activation on the 
electrical properties of the ventricular myocardium from 
that confounded by GLP-1R–mediated sympathetic acti-
vation and increases in HR, ventricular MAP was record-
ed in conditions of fixed ventricular pacing. With HR 
fixed between the conditions, Iso reduced APD90 from 
50.5±1.9 to 45.2±1.8 ms (P=0.014; Figure 1Dii). Subse-
quent administration of Ex4 resulted in a significant pro-
longation of paced APD90 from 44.6±1.4 to 51.1±1.9 ms 
Figure 2. Effects of GLP-1 (glucagon-like peptide-1) receptor activation on atrial rate and electrical properties of the ventricular myocardium ex vivo. 
A, Experimental protocols in isolated perfused hearts. Arrows depict time points when physiological measurements were taken; (B) Representative recordings of 
monophasic action potential illustrating the effects of isoproterenol (Iso; 100 nmol/L), exendin-4 (Ex4; 3 nmol/L), and coadministration of Iso (100 nmol/L) and Ex4 
(3 nmol/L) on paced action potential duration at 90% repolarization (APD90) in isolated hearts; (C) Effects of Iso and Ex4 on atrial rate in isolated hearts; Summary 
data showing the effects of Iso, Ex4, and coadministration of Iso and Ex4 on paced APD90 in the absence (D) and presence of atropine (1 μmol/L, E) or L-N
G-mono-
methyl arginine (L-NMMA, 100 μmol/L, F). P values indicate the level of significance compared with baseline condition.
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(P=0.044; Figure 1Dii). Atenolol had no effect on paced 
APD90 in conditions of systemic Ex4 action (47.0±1.4 
ms; P=0.314); however, the effect of Ex4 on APD90 was 
reversed by atropine and 7-nitroindazole (to 42.9±2.2 
and 38.4±1.4 ms, respectively; P=0.02).
In a separate experiment, systemic administration 
of dobutamine (1.5 mg/kg intraperitonially) reduced 
paced APD90 from 52.4±1.2 to 43.5±1.8 ms (P=0.008; 
n=5). Ex4 effectively reversed the effect of β-AR stim-
ulation on paced APD90 (increase from 43.5±1.8 to 
52.2±1.1 ms; P=0.005 and P=0.952 compared with 
baseline; Figure 1E).
Effects of GLP-1R Agonist Ex4 on Atrial 
Rate and Electrical Properties of the 
Ventricular Myocardium Ex Vivo
In the isolated heart preparation, Iso (100 nmol/L) 
increased atrial rate (from 243±12 to 341±17 bpm; 
P=0.003; n=6) while Ex4 (3 nmol/L) had no effect 
(232±13 versus 243±12 bpm; P=0.545; Figure 2C).
Iso reduced paced APD90 from 46.2±0.5 to 43.2±0.8 
ms (P=0.003). Ex4 had an opposite effect and increased 
APD90 to 49.4±1.0 ms (P=0.015 compared with base-
line; Figure 2D). Combined application of Iso and Ex4 
had no effect on APD90 when compared with baseline 
(46.4±0.6 versus 46.2±0.5 ms; P=0.976; Figure  2D). 
The effects of Ex4 on APD90 in the absence and pres-
ence of β-AR agonist Iso were prevented by atropine 
(1 μmol/L; n=6) and NO synthase inhibitor L-NG-mono-
methyl arginine (100 μmol/L; n=6; Figure 2E and 2F).
Effect of GLP-1R Agonist Ex4 on the 
Ventricular Arrhythmia Potential
In isolated heart preparation, Iso increased ventricular 
tachycardia inducibility during restitution pacing from 
0/18 hearts at baseline to 6/18 (P=0.007 χ2, P=0.019 
Fisher exact test; Figure 3). In 6 hearts, coadministration 
of Ex4 with Iso rendered ventricular tachycardia nonin-
ducible (0/6 Ex4+Iso versus 3/6 Iso alone, P=0.046 χ2, 
P=0.182 Fisher exact test; Figure 3A and 3B). In 12 hearts, 
treatment with either atropine or L-NG-monomethyl argi-
nine abolished the effects of Ex4 (Figure 3C and 3D).
DISCUSSION
In this study, we investigated the effects of a prototypi-
cal GLP-1R agonist Ex4 on tissue-level ventricular elec-
trophysiology in the rat heart. APD was assessed from 
MAPs recorded during sinus rhythm and during ventricu-
lar pacing. Consistent with the previously reported data,5 
systemic actions of Ex4 in vivo increased HR, and this 
effect was abolished by β-AR blockade. In contrast to the 
effect of Iso, Ex4 prolonged APD. This effect was more 
pronounced in fixed HR conditions where Ex4 markedly 
increased APD and effectively counteracted the effect of 
pharmacological β-AR stimulation on the heart. Similarly, 
in isolated heart preparation, Ex4 prolonged APD and 
prevented the effect of Iso on APD, but had no effect on 
HR. Furthermore, Ex4 decreased arrhythmia inducibility 
in conditions of simulated sympathetic activation mim-
icked by application of β-AR agonist Iso.
GLP-1R is coupled to the stimulatory G-proteins, and 
the actions of GLP-1 or GLP-1 analogues lead to activa-
tion of protein kinase A signaling pathway,18 similar to 
that recruited by β-AR stimulation. However, the effect 
of Ex4 on APD is opposite to that of β-AR agonists, 
and this is consistent with the current view that GLP-
1R are not expressed by ventricular myocytes.11 Thus, 
the effects of Ex4 on ventricular electrical properties are 
likely to be mediated by GLP-1Rs expressed by tissues 
extrinsic to cardiac myocytes.
That the effect of Ex4 on ventricular APD is preserved in 
isolated perfused heart preparation suggests that this GLP-
1R agonist may act on either coronary blood vessels (vas-
cular endothelium or smooth muscle) or the nerves which 
originate from the intrinsic cardiac ganglia and provide 
innervation of the ventricular system.19,20 Identification 
of the exact mechanism would require new approaches, 
such as conditional deletion of GLP-1Rs from the target 
tissue using mouse models. However, our pharmacologi-
cal analysis suggests that Ex4 is likely acting on parasym-
pathetic (vagal) neurons of the intrinsic cardiac ganglia 
which release acetylcholine and NO from their ventricular 
terminals. Indeed, the effects of Ex4 on APD were reversed 
or prevented by either muscarinic blockade or inhibition of 
the neuronal NO synthase. These effects are consistent 
with vagal modulation of ventricular excitability medi-
ated by the actions of acetylcholine and NO.21,22
The exact mechanisms of GLP-1R–mediated protec-
tive effects on ventricular arrhythmic potential remain 
to be determined. These may involve modulation of 
reentrant circuit path length through changes in cellular 
refractoriness. However, we have not examined chang-
es in conduction velocity or changes in calcium han-
dling that might underlie changes in abnormal impulse 
formation through delayed afterdepolarizations.
Interestingly, certain mutations, for example, in the 
gene encoding Kv11.1 voltage-gated K
+ channels cause 
long-QT syndrome 2 and simultaneously increase the 
production of GLP-1 by intestinal L cells.23 The data 
obtained in this study suggest that increased circulating 
GLP-1 in long-QT syndrome 2 may potentially be antiar-
rhythmic. However, it could also worsen the QT prolon-
gation under conditions of increased sympathetic drive, 
such as during exercise.
The use of GLP-1R agonists has been an important 
advance in the care of patients with type 2 diabe-
tes mellitus.1 Initially, there were concerns that these 
agents might worsen cardiovascular outcomes because 
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of sympathetic activation.24 However, there are no 
such indications and genomic studies support a clear 
negative association with the severity of cardiovascu-
lar disease.25 Furthermore, clinical studies have shown 
beneficial effects of GLP-1R agonists on cardiovascular 
disease markers, including atherogenic marker apolipo-
protein B.26 This study reveals a potential antiarrhythmic 
effect of GLP-1R activation, consistent with previously 
described strong cardioprotective effects of GLP-1.2,6–9 
One potential complication with the use of the exist-
ing drugs is that they may increase sympathetic drive, 
which is generally considered to be maladaptive and 
detrimental, contributing to the development of cardio-
vascular disease. Thus, it would be important to deter-
mine the exact site of GLP-1 action on the heart and 
then try to target these specific receptor populations.
Acknowledged study limitations are related to the 
marked differences in action potential morphology 
between rodent heart and that of larger mammals, 
including humans, and potential species-specific dif-
ferences in GLP-1R expression in the heart. The first 
limitation can potentially be addressed by studying the 
effect of GLP-1R agonists in preparations of human ven-
tricular myocytes (eg, in organotypic cultured human 
cardiac slices),27 yet, these preparations might be lack-
ing key components, including intact cardiac vagal 
neurons and their ventricular projections, which (as the 
data of this study suggest) mediate the effects of GLP-1 
on the electrical properties of the ventricular myocar-
dium. Regarding potential species-specific differences 
in GLP-1R expression in the heart, earlier data obtained 
in rodents and primates largely agree that GLP-1Rs are 
Figure 3. Effect of GLP-1 (glucagon-like peptide-1) receptor activation on the ventricular arrhythmia potential. 
A, Representative recordings of restitution pacing to induce ventricular tachycardia (VT) in the presence of isoproterenol (Iso, 100 nmol/L). Coadministration of 
exendin-4 (Ex4, 3 nmol/L) protects against VT (top), and this effect of Ex4 is abolished by nitric oxide synthase blockade with L-N
G-monomethyl arginine (L-NMMA, 
100 μmol/L; bottom); Effects of Iso (100 nmol/L), Ex4 (3 nmol/L), and coadministration of Iso (100 nmol/L) and Ex4 (3 nmol/L) on VT inducibility in the absence (B) 
and presence of atropine (1 μmol/L, C) or L-NMMA (100 μmol/L, D). **P<0.01, n.s. indicates not significant.
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predominantly expressed in the atria.11,28,29 The most 
recent report concluded that human cardiac ventricles 
do express GLP-1Rs, but the identity of the ventricular 
cell types expressing the receptor remains unknown.12 
Ventricular GLP-1R mRNA transcripts detected in the 
RNA isolated from the ventricular tissue12 may reflect the 
expression of the receptor in cardiac nerve fibers which 
provide functional innervation of the ventricles.19,22,30–32
Taken together, the data obtained demonstrate that 
GLP-1R activation effectively opposes the effect of β-AR 
stimulation on cardiac APD and reduces the ventricular 
arrhythmic potential in conditions of sympathetic acti-
vation. The effects of GLP-1R activation on ventricular 
electrical properties appear to be indirect, mediated by 
acetylcholine and NO, and, therefore, can be explained 
by recruitment of cardiac vagal neuron activity.
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